MADRID, February 24, 2011 /PRNewswire/ --
- Yondelis(R) sales increase by 70 percent
- The Biopharmaceutical business reported 55 percent growth in sales with respect to 2009, accounting for 52 percent of the group total and exceeding the contribution from the Consumer Chemicals division
- Group net sales rose by 24.4 percent
- EBITDA improved 74 percent and net income attributable to the parent company rose 71.6 percent in 2010
Zeltia Group's net revenues totalled 153.5 million euro in 2010, 24.4 percent more than in 2009 (123.4 million euro). This performance is primarily attributable to a 70 percent increase in Yondelis(R) sales.
Net sales in the Biopharmaceutical business amounted to 79.4 million euro in 2010 (51.1 million euro in 2009), of which 72.1 million correspond to Yondelis(R) (43.8 million euro in 2009).
The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro in 2010, compared with 71.1 million euro in 2009).
EBITDA improved by 74 percent in 2010 to -3.9 million euro (-15.3 million euro in 2009).
Net income attributable to the parent company rose 71 percent with respect to 2009.
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marinebased drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.
This note is also available on the Zeltia web site: http://www.zeltia.com